Year archive

NFL Biosciences — 2023 filings

All 43 regulatory filings released by NFL Biosciences (ALNFL) in 2023, sourced directly from the official regulator.

43 Filings

2023 Period

2023 filings (43)

Filing	Released	Lang
NFL BIOSCIENCES: PRE-IND APPLICATION FILED WITH THE FDA IN THE UNITED STATES FOR NFL-301, INDICATED FOR REDUCING ALCOHOL CONSUMPTION Regulatory Filings	2023-12-19	English
NFL BIOSCIENCES : DÉPÔT D’UNE DEMANDE DE PRE-IND AUPRÈS DE LA FDA AUX ÉTATS-UNIS POUR NFL- 301 DÉDIÉ À LA RÉDUCTION DE LA CONSOMMATION D’ALCOOL Regulatory Filings	2023-12-19	French
NFL BIOSCIENCES : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2023 Interim / Quarterly Report H1 2023	2023-10-06	French
NFL BIOSCIENCES: 2023 FIRST-HALF BUSINESS AND EARNINGS UPDATE Interim / Quarterly Report H1 2023	2023-10-05	English
NFL BIOSCIENCES : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2023 Earnings Release H1 2023	2023-10-05	French
NFL BIOSCIENCES: PROMISING RESULTS OF THE PRECESTO CLINICAL TRIAL REVEALING A PROLONGED EFFECT FOR NFL-101 AND MODIFICATION OF THE STRATEGY FOR COMMUNICATING THE CESTO II STUDY RESULTS Earnings Release Q4 2023	2023-09-25	English
NFL BIOSCIENCES : RESULTATS PROMETTEURS DE L'ETUDE CLINIQUE PRECESTO REVELANT UN EFFET PROLONGE DE NFL-101 ET MODIFICATION DE LA STRATEGIE DE COMMUNICATION DES RESULTATS DE L’ETUDE CESTO II Earnings Release Q3 2023	2023-09-25	French
NFL BIOSCIENCES : DÉPÔT D’UNE DEMANDE DE BREVET AUX ÉTATS-UNIS DÉDIÉE À LA RÉDUCTION DE LA CONSOMMATION D’ALCOOL AVEC NFL-301 & PRÉPARATION D’UNE DEMANDE DE PRE-IND AUPRÈS DE LA FDA Regulatory Filings	2023-07-18	French
Nfl Biosciences: Patent Application Filed in the United States for Reducing Alcohol Consumption With Nfl-301 & Preparation of a Pre-Ind Application Submission With the Fda Regulatory Filings	2023-07-18	English
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ : 1er SEMESTRE 2023 Transaction in Own Shares	2023-07-11	French
NFL BIOSCIENCES CONFIRME LE RENOUVELLEMENT DE SON ELIGIBILITE AU PEA-PME Regulatory Filings	2023-07-11	French
NFL BIOSCIENCES : RENFORCEMENT D’UN ACTIONNAIRE FONDATEUR PAR EXERCICE DE BSPCE Share Issue/Capital Change	2023-07-05	French
NFL BIOSCIENCES: CO-FOUNDER SHAREHOLDER FURTHER STRENGTHENS HIS POSITION BY EXERCISING “BSPCE” WARRANTS Share Issue/Capital Change	2023-07-05	English
NFL BIOSCIENCES : MONTÉE AU CAPITAL DE GB HOLDING PAR EXERCICE DE BSA POUR 0,5 M€ ET ENGAGEMENT DE CONSERVATION D’ACTIONS Capital/Financing Update	2023-06-29	French
NFL BIOSCIENCES: GB HOLDING TAKES A STAKE IN THE COMPANY’S CAPITAL UPON THE EXERCISE OF SHARE SUBSCRIPTION WARRANTS AND PAYMENT OF 0.5M€, AND ALSO COMMITS TO A LOCK-UP Capital/Financing Update	2023-06-29	English
NFL BIOSCIENCES : COMPTE RENDU DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 27 JUIN 2023 AGM Information	2023-06-28	French
NFL BIOSCIENCES : RESULTS OF THE COMBINED GENERAL MEETING OF JUNE 27, 2023 AGM Information	2023-06-28	English
NFL BIOSCIENCES : Accord de délivrance de son brevet sur NFL-101 en Europe et validation du plan de développement clinique de NFL-101 par l’EMA Regulatory Filings	2023-06-21	French
NFL BIOSCIENCES: Approval for its patent to be granted on NFL-101 in Europe and approval of the clinical development plan for NFL-101 by the EMA Regulatory Filings	2023-06-21	English
NFL Biosciences : Modalités de mise à disposition et consultation des documents préparatoires à l'Assemblée Générale Mixte du 27 juin 2023 AGM Information	2023-06-09	French
NFL Biosciences : Finalisation des recrutements de l’étude PRECESTO Regulatory Filings	2023-05-09	French
NFL Biosciences: Recruitment completed for the PRECESTO study Regulatory Filings	2023-05-09	English
NFL Biosciences : Mise à disposition du Rapport Annuel au 31/12/2022 Audit Report / Information FY 2022	2023-04-28	French
NFL Biosciences : Activités & Résultats annuels 2022 Annual Report FY 2022	2023-04-25	French
NFL Biosciences: 2022 full-year business and earnings update Earnings Release FY 2022	2023-04-25	English
Évolution de la gouvernance de NFL Biosciences Board/Management Information	2023-02-27	French
Changes in the governance of NFL Biosciences Board/Management Information	2023-02-27	English
NFL BIOSCIENCES: Inclusion of the first volunteer in the PRECESTO study Investor Presentation	2023-02-22	English
NFL BIOSCIENCES : 1ère inclusion de volontaire dans l’étude PRECESTO Investor Presentation	2023-02-22	French
NFL Biosciences obtient 1,7 million d’euros de financement « Avance Innovation » auprès de Bpifrance Capital/Financing Update	2023-02-20	French
NFL Biosciences receives € 1.7 million in « Avance Innovation » funding from Bpifrance Capital/Financing Update	2023-02-20	English
NFL : bilan semestriel du contrat de liquidité 2ème semestre 2022 Transaction in Own Shares	2023-02-17	English
NFL Biosciences collabore avec le CEA Regulatory Filings	2023-02-02	French
NFL Biosciences collaborates with the CEA Regulatory Filings	2023-02-02	English
NFL BIOSCIENCES : Très fort succès de l’augmentation de capital de NFL Biosciences avec plus de 3 millions d’euros levés Share Issue/Capital Change	2023-01-31	French
NFL BIOSCIENCES: Very successful capital increase for NFL Biosciences with over €3 million raised Share Issue/Capital Change	2023-01-31	English
NFL Biosciences launches a round of fundraising for approximately 2.5 million euros Capital/Financing Update	2023-01-30	English
NFL Biosciences lance une levée de fonds d’environ 2,5 millions d’euros Capital/Financing Update	2023-01-30	French
NFL Biosciences : Agenda de communication financière du 1er semestre 2023 Report Publication Announcement	2023-01-17	French
NFL Biosciences: Financial calendar for the first half of 2023 Report Publication Announcement	2023-01-17	English
NFL Biosciences reçoit une subvention conjointe de l’Etat Français et de la Région Occitanie pour son étude clinique PRECESTO Regulatory Filings	2023-01-11	French
NFL Biosciences receives a joint grant from the French Government and the Occitanie Region for its PRECESTO clinical trial Capital/Financing Update	2023-01-11	English
NFL BIOSCIENCES : nombre d'actions et droits de vote au 31.12.2022 Share Issue/Capital Change	2023-01-04	French